| 产品编号 | bs-1638R |
| 英文名称 | CD59 Rabbit pAb |
| 中文名称 | CD59抗体 |
| 别 名 | CD59 glycoprotein; CD59 molecule(CD59 blood group); 1F5 antigen; 20 kDa homologous restriction factor; MAC-inhibitory protein; Membrane attack complex inhibition factor; Membrane inhibitor of reactive lysis; MEM43 antigen; MACIF; 1F5; EJ16; EJ30; EL32; G344; MIN1; MIN2; MIN3; MIRL; HRF20; MACIF; MEM43; MIC11; MSK21; 16.3A5; HRF-20; MAC-IP; p18-20; CD59_HUMAN. |
 |
Specific References (1) | bs-1638R has been referenced in 1 publications.
[IF=5.719] Lingzi Feng. et al. A Closed-Loop Autologous Erythrocyte-Mediated Delivery Platform for Diabetic Nephropathy Therapy. NANOMATERIALS-BASEL. 2022 Jan;12(20):3556 FC ; Rabbit.
|
| 研究领域 | 心血管 免疫学 信号转导 干细胞 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human |
| 产品应用 | Flow-Cyt=1μg /test
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 9 kDa |
| 检测分子量 | 19-25 |
| 细胞定位 | 细胞膜 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CD59: 52-100/128 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq, Jul 2008] Function: Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase. The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes. Subunit: Interacts with T-cell surface antigen CD2. Subcellular Location: Cell membrane; Lipid-anchor, GPI-anchor. Secreted. Note=Soluble form found in a number of tissues. Post-translational modifications: N- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. Also significant amounts of triantennary complexes (22%). Variable sialylation also present in the Asn-43 oligosaccharide. The predominant O-glycans are mono-sialylated forms of the disaccharide, Gal-beta-1,3GalNAc, and their sites of attachment are probably on Thr-76 and Thr-77. The GPI-anchor of soluble urinary CD59 has no inositol-associated phospholipid, but is composed of seven different GPI-anchor variants of one or more monosaccharide units. Major variants contain sialic acid, mannose and glucosamine Sialic acid linked to an N-acetylhexosamine-galactose arm is present in two variants. Glycated. Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects. Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes. DISEASE: CD59 deficiency (CD59D) [MIM:612300]: A deficiency resulting in chronic complement-mediated intravascular hemolysis, anemia, hemoglobinuria and thrombosis. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Contains 1 UPAR/Ly6 domain. SWISS: P13987 Gene ID: 966 Database links: Entrez Gene: 966 Human Entrez Gene: 12509 Mouse Omim: 107271 Human SwissProt: P13987 Human SwissProt: O55186 Mouse Unigene: 278573 Human Unigene: 709466 Human Unigene: 710641 Human Unigene: 247265 Mouse 反应性溶血膜抑制蛋白（CD59）是血细胞膜上糖化磷脂酰肌醇（GPI）锚定蛋白，具有抑制补体系统激活，参与信号传递，有协助T淋巴细胞活化功能,CD59在补体调节过程中起着很主要的作用。 |
| 产品图片 |
Blank control: 293T(blue). Primary Antibody(green):Rabbit Anti- CD59 antibody(bs-1638R), Dilution: 1μg in 100 1μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG(orange) ,used under the same conditions ); Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA.
Protocol
The cells were washed twice with phosphate-buffered saline (PBS).The cells were then incubated in 1 X PBS containing 0.5% BSA + 1 0% goat serum (15 min) to block non-specific protein-protein interactions followed by the antibody (bs-1638R, 5μg /1x10^6 cells) for 30 min on ice. The secondary antibody used was Goat Anti-rabbit IgG/PE antibody at 1/200 dilution for 30 min on ice. Acquisition of 20,000 events was performed.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
